Efgartigimod (efgartigimod alfa-fcab, Vyvgart<sup>™</sup>) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. In December 2021, intravenous efgartigimod received its first approval in the USA for the tre...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!